Navigation Links
Janssen Therapeutics Announces Recipient of Its Second Point Scholarship for LGBT Students

TITUSVILLE, N.J., July 16, 2013 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced today the recipient of the second scholarship the company is supporting through the Point Foundation, the nation's largest scholarship-granting organization for lesbian, gay, bisexual and transgender (LGBT) students of merit. Janssen is the first pharmaceutical company to fund a Point Scholarship.  

The Point Scholarship supported by Janssen is for LGBT students whose field of study is focused on HIV/AIDS, or who have chosen to attend business school. It has been awarded to Michael Haymer of Orange County, California. Michael is pursuing a joint MD-MBA degree from the PRIME Program at the David Geffen School of Medicine at University of California, Los Angeles (UCLA).

The Point Scholarship is granted for a four-year period to graduating high school seniors and college students. As a Point Scholar, Michael will receive financial assistance and will be matched with a successful professional who can serve as his mentor and role model.

Michael and his four siblings were raised by their single mother who died from complications of undertreated diabetes during his first year of medical school. As a tribute to her, Michael focused his studies on serving under-resourced and vulnerable populations. 

"I'm personally committed to my research and work as a community educator in the areas of LGBT and HIV health because I know firsthand how important it is to give a voice to underserved populations," said Michael. "With this scholarship, I look forward to setting an example for other LGBT students interested in healthcare and continuing the tradition of Point Scholars."

Michael has a particular interest in the area of transgender healthcare. He directed the LGBT Health Student Symposium, which hosted more than 100 students from across the country. In recognition of his efforts, Michael received the UCLA Diversity, Equity & Inclusion Award.  

Michael also has experience in HIV research; he served as a community educator for an international HIV vaccine trial and conducted research on the use of mobile technology to improve community outreach methods for HIV/AIDS prevention.

In 2012, Janssen provided a Point Scholarship to medical student Siddarth (Sid) Puri to support his studies at University of California Davis School of Medicine. Sid was named co-director, class of 2014, of the student-run Joan Viteri Memorial Clinic dedicated to serving the healthcare needs of uninsured drug users. The Point Scholarship helps Sid advance his efforts to provide culturally sensitive medical care to the LGBT community and people living with HIV/AIDS.

"Since the start of the HIV epidemic, the LGBT community has played a leadership role in mobilizing the response. While great progress has been made, more than 30 years later HIV infection rates are rising among men who have sex with men and communities of color," said Ron Falcon, MD, Director of Marketing, HIV, Janssen. "Through the Point Foundation scholarship, Janssen is investing to help develop the next generation of leaders from the LGBT community to continue the fight against HIV."

About Janssen Therapeutics
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in HIV and other infectious diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Headquartered in Titusville, New Jersey, Janssen Therapeutics, Division of Janssen Products, LP, is one of the Janssen Pharmaceutical Companies. Visit for more information and follow us on Twitter at @JanssenUS.

Media Contact:
Pamela Van Houten
Phone: (609) 730-7902

SOURCE Janssen Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Second Genome Announces Agreement with Janssen on Microbiome Drug Discovery in Ulcerative Colitis
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
4. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
5. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
6. Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
7. Janssen Pharmaceutica, NV, Funds New Global Mental Health Scholarships as Part of Its Healthy Minds Program
8. Janssen Neuroscientists and Colleagues Challenge Healthcare Industry to Create Integrated Approaches to Healthcare Innovation in Newly Published Article
9. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
11. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
Post Your Comments:
(Date:10/13/2015)... 9, 2015 Research and Markets ( ... Market by Types (Bacteria, Yeast, Mold, Others), Flavors (Herbs ... Others), & by Region - Forecasts to 2020" ... --> --> The global market ... years. In terms of value, the market is projected ...
(Date:10/13/2015)... -- anesthesia and respiratory devices market ... according to a new report by Grand View Research, ... to resolve various environmental and lifestyle induced respiratory disorders ... anesthesia and respiratory devices market is expected ... a new report by Grand View Research, Inc. Anesthesia ...
(Date:10/13/2015)... , Oct. 13, 2015   Happy ... direct-to-consumer laboratory home testing kit for breast ... technologies provide an unparalleled, detailed assessment of ... milk—fats, proteins, carbs and key vitamins—all charted ... for personal health tracking.  In addition, Happy Vitals ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... NavaFit Inc. today announced the launch of its ... with, participate in local fitness & sporting events, and stay motivated. Users ... medical costs drive us to get more serious about fitness and wellness, individuals are ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... Anik Singal's newly launched "Publish Academy" training course . Singal's new program, ... for enrollment today, and marketers around the Internet are weighing in with reviews. ...
(Date:10/13/2015)... CA (PRWEB) , ... October 13, 2015 , ... ... and workflow solutions, announced today their Title Sponsorship of Synergy 2015. The annual ... Henderson, NV at Green Valley Ranch and will unite customers, partners, WennSoft team ...
(Date:10/13/2015)... ... ... Scientists in Seattle and Vancouver compared the diagnostic value of lung fluid ... Mesothelioma has just posted an article on the new research. Click here to ... University of British Columbia found that certain genetic alterations were seen just as often ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... of telemedicine programs in communities throughout Georgia, along with affiliate organizations, Alabama Partnership ... for their regional telehealth summits for Fall 2015. , Each of the ...
Breaking Medicine News(10 mins):